NewAmsterdam Pharma
在场
NewAmsterdam Pharma 是一家在股票代码 NAMS (NL) 下上市的公司。
高管
查看带有其 22 名主要高管的组织结构图
NewAmsterdam Pharma 搜索最多的简介
- Michael Davidson, Chief Executive Officer and Director
- Sander Van Slootweg, Director
- Nicholas Downing, Director
高管在NewAmsterdam Pharma变化
- Juliette Audet 曾任 Director, 现升职为 Chief Business Officer (新闻发布的2024四月2号).
- William Lewis已作为Chairman of the Board加入公司 (新闻发布的2024一月9号).
- Ian Somaiya已作为Chief Financial Officer加入公司 (新闻发布的2023十月24号).
创建提醒
跟踪 NewAmsterdam Pharma 的高管变动
药店
NewAmsterdam Pharma 拥有 1,861 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- MedMen has filed for bankruptcy protection (公布2024四月28号).
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
药店 行业的其他推荐联系人
消息
NewAmsterdam Pharma 的最新新闻稿
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | NewAmsterdam Pharma Company
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients | NewAmsterdam Pharma Company N.V.
- View more press releases Close
通过电子邮件
